<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-29T16:45:12+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【招募患者】评价C019199片在实体瘤中的安全性、耐受性、PK和抗肿瘤活性的多中心、开放、剂量递增的I期临床研究</title>
    <updated>2020-11-29T09:12:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/VAU_SXuw1Twmo4tN_3vKHg</id>
    <link href="https://mp.weixin.qq.com/s/VAU_SXuw1Twmo4tN_3vKHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项在成人斑秃患者中评价SHR0302片的有效性和安全性的随机、双盲和安慰剂对照Ⅱ期研究</title>
    <updated>2020-11-29T09:12:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/ALvbRPYGghdoickKUKSj_Q</id>
    <link href="https://mp.weixin.qq.com/s/ALvbRPYGghdoickKUKSj_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达PD-1、PD-L1双抗招募患者4】IBI318联合常规TACE围手术期治疗潜在可切除的肝细胞癌安全性和有效性的Ib期研究</title>
    <updated>2020-11-28T18:04:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-28:/s/j7n01XSGXhuASw_uh6lDbQ</id>
    <link href="https://mp.weixin.qq.com/s/j7n01XSGXhuASw_uh6lDbQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达PD-1、PD-L1双抗招募患者3】IBI318治疗晚期皮肤鳞状细胞癌有效性和安全性的单臂、开放、多中心、Ib/II期研究</title>
    <updated>2020-11-27T10:48:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/q8NeH-4hRR4nMdvjmRxf8w</id>
    <link href="https://mp.weixin.qq.com/s/q8NeH-4hRR4nMdvjmRxf8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国产新冠疫苗向药监局提出上市申请</title>
    <updated>2020-11-26T07:17:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/Cqy7Npnkf4Eg4P3AIX3QWg</id>
    <link href="https://mp.weixin.qq.com/s/Cqy7Npnkf4Eg4P3AIX3QWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【信达PD-1、PD-L1双抗招募患者2】评估IBI318治疗复发难治结外NK/T细胞淋巴瘤（鼻型）疗效安全Ib/II期临床研究</title>
    <updated>2020-11-26T07:17:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/k_2xMZZdciuy9sC6dnV95Q</id>
    <link href="https://mp.weixin.qq.com/s/k_2xMZZdciuy9sC6dnV95Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在非小细胞肺癌评估 JNJ-73841937单药治疗或与JNJ-61186372联合治疗安全性和PK I/Ib期研究</title>
    <updated>2020-11-25T08:02:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/7rLzY0mw7-rcKN3ZybOvoA</id>
    <link href="https://mp.weixin.qq.com/s/7rLzY0mw7-rcKN3ZybOvoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价BI655130与安慰剂相比在具有泛发性脓疱性银屑病病史的患者中预防GPP发作的有效性和安全性的IIb期研究</title>
    <updated>2020-11-25T08:02:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/qseNj-uz3MOeTY1zdqYQQA</id>
    <link href="https://mp.weixin.qq.com/s/qseNj-uz3MOeTY1zdqYQQA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】SHR3680联合多西他赛治疗前列腺癌的II期临床研究</title>
    <updated>2020-11-24T08:30:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/Gnd1Cyy2dbRv0Y7Q8pfAuw</id>
    <link href="https://mp.weixin.qq.com/s/Gnd1Cyy2dbRv0Y7Q8pfAuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价Tildrakizumab治疗中度至重度斑块状银屑病的疗效及安全性的随机、双盲、安慰剂对照、多中心临床试验</title>
    <updated>2020-11-24T08:30:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/c3hWyYJDoAMCFN1917eAcw</id>
    <link href="https://mp.weixin.qq.com/s/c3hWyYJDoAMCFN1917eAcw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】AB-106 治疗携带NTRK 融合基因的局部进展或全身转移的实体瘤受试者的一项Ⅱ期、多中心、开放、篮式研究</title>
    <updated>2020-11-23T08:09:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/L9o59_RokkzPCnHQGpTv1A</id>
    <link href="https://mp.weixin.qq.com/s/L9o59_RokkzPCnHQGpTv1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】注射用紫杉醇（白蛋白结合型）在乳腺癌患者中的随机、开放、单剂量、多中心、两周期、两交叉生物等效性研究</title>
    <updated>2020-11-22T08:34:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/xq9emeEX12CbhSknO0oAog</id>
    <link href="https://mp.weixin.qq.com/s/xq9emeEX12CbhSknO0oAog" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】对比DCC-2618与舒尼替尼在伊马替尼治疗后的胃肠道间质瘤中的有效性、安全性的随机、开放、多中心II期临床研究</title>
    <updated>2020-11-21T07:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/QeYCj68y4Yoz1w2GeM5iqQ</id>
    <link href="https://mp.weixin.qq.com/s/QeYCj68y4Yoz1w2GeM5iqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在轻中度特应性皮炎患者中评估 2% CRISABOROLE 软膏疗效和安全的Ⅲ期、多中心、随机、双盲、赋形剂对照研究</title>
    <updated>2020-11-21T07:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/Ny_lztlrdGPEx1hDHwt5gw</id>
    <link href="https://mp.weixin.qq.com/s/Ny_lztlrdGPEx1hDHwt5gw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【合源CAR-T招募3】CNCT19细胞注射液治疗复发或难治性非霍奇金淋巴瘤的II期临床试验</title>
    <updated>2020-11-20T07:28:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/1KDkebBJhbnavEPuumHi1w</id>
    <link href="https://mp.weixin.qq.com/s/1KDkebBJhbnavEPuumHi1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价福瑞他恩（KX-826）酊治疗中国成年男性雄激素性秃发（AGA）的安全性、有效性的II期临床试验方案</title>
    <updated>2020-11-20T07:28:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ucTM7FvQYts7oTWB2FlMhg</id>
    <link href="https://mp.weixin.qq.com/s/ucTM7FvQYts7oTWB2FlMhg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>